Within the current context of falling public spending on pharmaceuticals, the contribution of value becomes a determining factor in ensuring the pharmaceutical industry’s success. The extension of the services associated with efficiency improvements in medicine use is particularly important.
The spending cuts policies being implemented by health authorities provide the backdrop to actions with healthcare providers to develop joint projects with shared risk strategies.
The new pharmaceutical policy scenario, with changes in the decision-making process and new decision- making players at central and regional level, has forced the pharmaceutical industry to define its market access strategy, tailoring it to each type of product and therapeutic area.
The recent reform of the Penal Code, in relation to acts by employees, may entail penalties for legal entities and make it impossible for them to do business with the Public Administrations or lead to the suspension / cancellation of the necessary administrative business authorisations.
The current context characterised by a general delay in payment by the Public Administrations is driving companies in the pharmaceutical industry to systematically claim debts and late-payment interest on regular basis in order to minimise the related financial risks.
Corporate income tax legislation provides a tax reduction for the assignment of intangibles of special interest for companies in the pharmaceutical industry provided that they create technical knowhow and are assigned for consideration.
